Wikisage, the free encyclopedia of the second generation, is digital heritage

Epilepsy: Difference between revisions

From Wikisage
Jump to navigation Jump to search
mNo edit summary
(world health Org)
Line 7: Line 7:
It is difficult to distinguish between genetic and cryptogenic syndromes.
It is difficult to distinguish between genetic and cryptogenic syndromes.


Morbility data is difficult to interpret when WHO states 50 millions persons affect by '''epilepsy'''<ref>(Chung 2015)</ref>
Morbility data is difficult to interpret when WHO<ref>http://www.who.int/en/</ref> states 50 millions persons affect by '''epilepsy'''<ref>(Chung 2015)</ref>


nonadherence appears to be associated with increased health care costs,nevertheless XR-medicine appears as strategy to overcome compliance wih [[antiepileptic drug|AED]]<ref>(Davis et al 2008)</ref>
nonadherence appears to be associated with increased health care costs,nevertheless XR-medicine appears as strategy to overcome compliance wih [[antiepileptic drug|AED]]<ref>(Davis et al 2008)</ref>

Revision as of 17:18, 25 July 2015

Classification of ethiology could divided in four categories:

  • idiopathic epilepsy
  • symptomatic epilepsy
  • provoked epilepsy
  • cryptogenic epilepsy

[1] It is difficult to distinguish between genetic and cryptogenic syndromes.

Morbility data is difficult to interpret when WHO[2] states 50 millions persons affect by epilepsy[3]

nonadherence appears to be associated with increased health care costs,nevertheless XR-medicine appears as strategy to overcome compliance wih AED[4]

Medicines

type  ,,, ,,,,
INN  Generic slow release
carbamazepine  normal xr
lamotrigine  normal xr
levetiracetam  normal xr
oxcarbazepine  ... xr
phenitoin  ... xr
valproate  xr
topiramat  xr

AED

ILAE Classification

[5] [6] A new perspective for Epileptic Disorders

Links

Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population Dravet's syndrome


References

References: